JP2016505012A - Ｉｒａｋ阻害剤およびその使用 - Google Patents

Ｉｒａｋ阻害剤およびその使用 Download PDF

Info

Publication number
JP2016505012A
JP2016505012A JP2015552741A JP2015552741A JP2016505012A JP 2016505012 A JP2016505012 A JP 2016505012A JP 2015552741 A JP2015552741 A JP 2015552741A JP 2015552741 A JP2015552741 A JP 2015552741A JP 2016505012 A JP2016505012 A JP 2016505012A
Authority
JP
Japan
Prior art keywords
compound
ring
nitrogen
oxygen
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015552741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505012A5 (enExample
Inventor
ジェレミー ロバート グレーンウッド，
ジェレミー ロバート グレーンウッド，
ジェラルディーン シー． ハリマン，
ジェラルディーン シー． ハリマン，
ロサナ カペラー−リバーマン，
ロサナ カペラー−リバーマン，
クレッグ イー． マッス，
クレッグ イー． マッス，
ショーネッシー ロビンソン，
ショーネッシー ロビンソン，
ドナ エル． ロメロ，
ドナ エル． ロメロ，
ミー シェリー，
ミー シェリー，
ロナルド ティー． ウェスタ—，
ロナルド ティー． ウェスタ―，
Original Assignee
ニンバス アイリス， インコーポレイテッド
ニンバス アイリス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニンバス アイリス， インコーポレイテッド, ニンバス アイリス， インコーポレイテッド filed Critical ニンバス アイリス， インコーポレイテッド
Publication of JP2016505012A publication Critical patent/JP2016505012A/ja
Publication of JP2016505012A5 publication Critical patent/JP2016505012A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015552741A 2013-01-10 2014-01-08 Ｉｒａｋ阻害剤およびその使用 Pending JP2016505012A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361751000P 2013-01-10 2013-01-10
US61/751,000 2013-01-10
PCT/US2014/010652 WO2014110114A1 (en) 2013-01-10 2014-01-08 Irak inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2016505012A true JP2016505012A (ja) 2016-02-18
JP2016505012A5 JP2016505012A5 (enExample) 2017-02-09

Family

ID=51061425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552741A Pending JP2016505012A (ja) 2013-01-10 2014-01-08 Ｉｒａｋ阻害剤およびその使用

Country Status (9)

Country Link
US (2) US9175007B2 (enExample)
EP (1) EP2943202A4 (enExample)
JP (1) JP2016505012A (enExample)
CN (1) CN105142639A (enExample)
AU (1) AU2014205577A1 (enExample)
BR (1) BR112015014034A2 (enExample)
CA (1) CA2890911A1 (enExample)
HK (1) HK1216859A1 (enExample)
WO (1) WO2014110114A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019383845B2 (en) * 2018-11-21 2023-02-02 Korea Research Institute Of Chemical Technology Novel tricyclic compound as IRAK4 inhibitor

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ753024A (en) 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
JP2016505012A (ja) * 2013-01-10 2016-02-18 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
BR112017001677A2 (pt) * 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102048719B1 (ko) * 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2019001461A1 (zh) * 2017-06-27 2019-01-03 南京明德新药研发股份有限公司 Irak4抑制剂
EP3645525A1 (en) * 2017-06-29 2020-05-06 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
KR102891608B1 (ko) * 2018-11-30 2025-11-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
US20220252574A1 (en) * 2019-07-22 2022-08-11 University Of Louisville Research Foundation, Inc. Immunomodulatory compositions and methods of using
TW202245789A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
WO2023075479A1 (ko) * 2021-10-28 2023-05-04 재단법인 대구경북첨단의료산업진흥재단 신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
IL315677A (en) 2022-03-23 2024-11-01 Rigel Pharmaceuticals Inc Pyrimid-2-yl-pyrazole compounds as irak inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1937459A1 (de) 1968-08-02 1970-02-05 Ciba Geigy Neue Pyrimidinderivate und Verfahren zu ihrer Herstellung
US5948911A (en) 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
KR20010105399A (ko) 1999-03-30 2001-11-28 쓰끼하시 다미까따 티에노피리미딘 화합물 및 그의 염, 및 그들의 제조 방법
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CN101100472A (zh) 2001-04-30 2008-01-09 美国拜尔公司 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
AU2002360774A1 (en) 2001-12-28 2003-07-24 Bayer Corporation 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
AU2003270701B2 (en) 2002-10-31 2009-11-12 Amgen Inc. Antiinflammation agents
EP1622914B1 (en) 2003-03-31 2011-06-01 Trovis Pharmaceuticals LLC New piperidinylamino-thieno[2,3-d] pyrimidine compounds
WO2005037213A2 (en) 2003-10-14 2005-04-28 Cornell Research Foundation, Inc. Antiinflammatory inhibitors of respiratory burst in adherent neutrophils
US7598259B2 (en) 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
EP1773840B1 (de) 2004-07-23 2010-01-20 The Medicines Company (Leipzig) GmbH Substituierte pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und pyrido[3',2':4,5]furo[3,2-d]-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
WO2006081072A1 (en) 2005-01-24 2006-08-03 Abbott Laboratories Antagonists of the mglu receptor and uses thereof
CA2655799A1 (en) 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007024593A1 (en) 2005-08-19 2007-03-01 Schering Corporation Fused tricyclic mglur1 antagonists as therapeutic agents
CA2619419A1 (en) 2005-08-19 2007-03-22 Schering Corporation Fused tricyclic mglur1 antagonists as therapeutic agents
CA2668997C (en) * 2006-11-09 2012-10-09 Ardea Biosciences, Inc. 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
US20100227853A1 (en) 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
US20100063047A1 (en) 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
EP2509597A4 (en) 2009-12-10 2013-04-10 Univ North Carolina SELECTIVE BETA-GLUCURONIDASE INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF ANTINEOPLASTIC CAMPTOTHECIN MEDICAMENTS
BR112013000868A2 (pt) 2010-07-13 2016-05-17 Hoffmann La Roche derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
CA2808432C (en) 2010-07-23 2019-06-04 President And Fellows Of Harvard College Tricyclic proteasome activity enhancing compounds with thieno[2,3-d]pyrimidine core
WO2013078126A1 (en) 2011-11-23 2013-05-30 Cancer Research Technology Limited Thienopyrimidine inhibitors of atypical protein kinase c
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP2015528801A (ja) 2012-07-11 2015-10-01 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
JP2016505012A (ja) * 2013-01-10 2016-02-18 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
WO2014194242A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Flt3 inhibitors and uses thereof
WO2014194245A2 (en) * 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120283238A1 (en) * 2011-01-10 2012-11-08 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6126131B2 (ja) * 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019383845B2 (en) * 2018-11-21 2023-02-02 Korea Research Institute Of Chemical Technology Novel tricyclic compound as IRAK4 inhibitor
US12378250B2 (en) 2018-11-21 2025-08-05 Korea Research Institute Of Chemical Technology Tricyclic compound as IRAK4 inhibitor

Also Published As

Publication number Publication date
US20140194417A1 (en) 2014-07-10
US20160068543A1 (en) 2016-03-10
WO2014110114A1 (en) 2014-07-17
CN105142639A (zh) 2015-12-09
EP2943202A1 (en) 2015-11-18
AU2014205577A1 (en) 2015-05-28
US9751892B2 (en) 2017-09-05
CA2890911A1 (en) 2014-07-17
BR112015014034A2 (pt) 2017-07-11
US9175007B2 (en) 2015-11-03
EP2943202A4 (en) 2016-08-24
HK1216859A1 (zh) 2016-12-09

Similar Documents

Publication Publication Date Title
US9751892B2 (en) IRAK inhibitors and uses thereof
US9518065B2 (en) IRAK inhibitors and uses thereof
US9790234B2 (en) IRAK inhibitors and uses thereof
US10968236B2 (en) TYK2 inhibitors and uses thereof
JP6126131B2 (ja) Ｉｒａｋ阻害剤およびその使用
US9067948B2 (en) IRAK inhibitors and uses thereof
US9340554B2 (en) IRAK inhibitors and uses thereof
WO2017004133A1 (en) Irak inhibitors and uses thereof
JP2017513954A (ja) Ｉｒａｋ阻害剤およびその使用
US20140018361A1 (en) Irak inhibitors and uses thereof
WO2017004134A1 (en) Irak inhibitors and uses thereof
WO2014194242A2 (en) Flt3 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180629